AU2003267722A1 - Imidazol-1-ylmethyl pyridazine derivatives - Google Patents

Imidazol-1-ylmethyl pyridazine derivatives

Info

Publication number
AU2003267722A1
AU2003267722A1 AU2003267722A AU2003267722A AU2003267722A1 AU 2003267722 A1 AU2003267722 A1 AU 2003267722A1 AU 2003267722 A AU2003267722 A AU 2003267722A AU 2003267722 A AU2003267722 A AU 2003267722A AU 2003267722 A1 AU2003267722 A1 AU 2003267722A1
Authority
AU
Australia
Prior art keywords
imidazol
ylmethyl
pyridazine derivatives
pyridazine
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003267722A
Other languages
English (en)
Other versions
AU2003267722A8 (en
Inventor
Bingson Han
George Maynard
Linghong Xie
Yuelian Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurogen Corp
Original Assignee
Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp filed Critical Neurogen Corp
Publication of AU2003267722A8 publication Critical patent/AU2003267722A8/xx
Publication of AU2003267722A1 publication Critical patent/AU2003267722A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2003267722A 2002-10-07 2003-10-06 Imidazol-1-ylmethyl pyridazine derivatives Abandoned AU2003267722A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60/416,660 2002-10-01
US41666002P 2002-10-07 2002-10-07
PCT/IB2003/004382 WO2004031174A1 (en) 2002-10-07 2003-10-06 Imidazol-1-ylmethyl pyridazine derivatives

Publications (2)

Publication Number Publication Date
AU2003267722A8 AU2003267722A8 (en) 2004-04-23
AU2003267722A1 true AU2003267722A1 (en) 2004-04-23

Family

ID=32069951

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003267722A Abandoned AU2003267722A1 (en) 2002-10-07 2003-10-06 Imidazol-1-ylmethyl pyridazine derivatives

Country Status (7)

Country Link
US (1) US7122546B2 (enExample)
EP (1) EP1549636A1 (enExample)
JP (1) JP2006504714A (enExample)
CN (1) CN100579579C (enExample)
AU (1) AU2003267722A1 (enExample)
CA (1) CA2495698A1 (enExample)
WO (1) WO2004031174A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2495708A1 (en) * 2002-11-08 2004-05-21 Neurogen Corporation 4-imidazol-1-ylmethyl-pyrimidine derivatives as ligands for gabaa receptors
JP2006517958A (ja) 2003-02-19 2006-08-03 ニューロジェン・コーポレイション アリール酸ピリミジニルメチルアミド、ピリダジニルメチルアミドおよび関連化合物
AU2004261591A1 (en) * 2003-07-25 2005-02-10 Neurogen Corporation Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands
JP4836280B2 (ja) 2004-06-18 2011-12-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 癌を治療するためのキネシンスピンドルタンパク質（ｋｓｐ）阻害剤としてのｎ−（１−（１−ベンジル−４−フェニル−１ｈ−イミダゾール−２−イル）−２，２−ジメチルプロピル）ベンズアミド誘導体および関連化合物
AU2008205169B2 (en) 2007-01-05 2012-02-02 Novartis Ag Imidazole derivatives as kinesin spindle protein inhibitors (Eg-5)
MX2009007661A (es) 2007-01-19 2009-12-14 Ardea Biosciences Inc Inhibidores de mek.
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
RU2705556C2 (ru) * 2012-12-21 2019-11-07 Келверум Инк. Нереплицируемые происходящие от вирусов частицы и их применение
AU2018244916B2 (en) 2017-03-30 2021-11-18 Bristol-Myers Squibb Company Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200959B1 (en) * 1996-12-04 2001-03-13 Powerject Vaccines Inc. Genetic induction of anti-viral immune response and genetic vaccine for filovirus
EP1121141A2 (en) * 1998-10-13 2001-08-08 Chiron Corporation Angiogenically effective unit dose of fgf and method of administering
WO2002002557A2 (en) * 2000-06-30 2002-01-10 Neurogen Corporation 2-phenylimidazo[1,2-a]pyridine derivatives: a new class of gaba brain receptor ligands
PA8535601A1 (es) * 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
US6982268B2 (en) 2002-05-08 2006-01-03 Neurogen Corporation Substituted imidazolylmethyl pyridine and pyrazine derivatives GABAA receptor ligands
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
CA2495708A1 (en) 2002-11-08 2004-05-21 Neurogen Corporation 4-imidazol-1-ylmethyl-pyrimidine derivatives as ligands for gabaa receptors
WO2004107863A1 (en) 2003-05-05 2004-12-16 Neurogen Corporation Sustituted imidazolopyrazine and triazolopyrazine derivatives: gabaa receptor ligands

Also Published As

Publication number Publication date
WO2004031174A8 (en) 2005-04-21
US20040077653A1 (en) 2004-04-22
JP2006504714A (ja) 2006-02-09
AU2003267722A8 (en) 2004-04-23
CN100579579C (zh) 2010-01-13
WO2004031174A1 (en) 2004-04-15
EP1549636A1 (en) 2005-07-06
US7122546B2 (en) 2006-10-17
CA2495698A1 (en) 2004-04-15
CN1717250A (zh) 2006-01-04

Similar Documents

Publication Publication Date Title
AU2003292429A1 (en) Pyrazole compounds
AU2003296586A1 (en) Pyridazinone derivatives as cdk2-inhibitors
AU2003224640A1 (en) Integrated putter system
PL371918A1 (en) Pyridazine derivatives
AU2003239909A1 (en) Enhanced-service provision
AU2003211362A1 (en) N-hydroxycarboxamide derivative
AU2003260919A1 (en) Azapurine derivatives
AU2003227712A1 (en) Tetrahydroisoquinoline derivatives
AU2003301968A1 (en) 4-aminomethyl-1-aryl-cyclohexylamine derivatives
AU2003273885A1 (en) Morpholine-bridged indazole derivatives
AU2003281039A1 (en) Imidazole derivative
AU2003278369A1 (en) 3-cyano-quinoline derivatives
AU2003296564A1 (en) 4-hydroxymethyl-1-aryl-cyclohexylamine derivatives
AU2003222659A1 (en) 23-o-substituted 5-o-mycaminosyltylonide derivatives
AU2003234131A1 (en) 5-o-mycaminosyltylonide derivatives
AU2003267722A1 (en) Imidazol-1-ylmethyl pyridazine derivatives
AU2003206730A1 (en) Fitting
AU2003227976A1 (en) Meeting aid
AU2003223475A1 (en) Substituted pyrazine derivatives
AU2003238180A1 (en) 2-naphtamide derivatives
AU2002249639A1 (en) Pyranocoumarin derivatives
AU2003273398A1 (en) Aroyl-piperidine derivatives
AU2002953019A0 (en) Azole derivatives
AU2002368112A1 (en) Pyrimidine derivatives
AU2003288012A1 (en) Isothiazolyl-benzoxazine derivatives

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase